Roche Announces $50 Billion Investment in U.S. Manufacturing and Research

BASel, Switzerland – Roche announced today it will invest $50 billion into the United States over the next five years. This significant investment aims to strengthen Roche’s existing operations, which include 13 manufacturing and 15 research and development sites across the U.S.

The company expects this investment will create more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 new positions at Roche facilities. Roche currently employs more than 25,000 people across 24 sites in eight states.

Thomas Schinecker, CEO of Roche Group, emphasized the commitment to U.S. operations in a statement, saying, “Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the U.S.” He described the investment as a foundation for a new era of innovation and growth that will benefit patients worldwide.

Roche plans to build a gene therapy manufacturing facility in Pennsylvania, a 900,000 square foot center for weight loss medicines, and a continuous glucose monitoring facility in Indiana. The company is also establishing a new AI-focused research and development center in Massachusetts for cardiovascular research.

Upon completion, Roche predicts that its U.S. exports of medicines will exceed imports. Currently, its diagnostics division already reports an export surplus from the U.S.

Founded in 1896 in Basel, Switzerland, Roche has emerged as a leader in biotechnology and diagnostics. The company states that it is committed to sustainability and aims to achieve net-zero emissions by 2045.